Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells
AssigneeAVI BioPharma, Inc.
InventorsDan V. Mourich, Patrick L. Iversen, Richard K. Bestwick
Life of this patent
Estimating the term…
Loading patent…
AssigneeAVI BioPharma, Inc.
InventorsDan V. Mourich, Patrick L. Iversen, Richard K. Bestwick
Estimating the term…
A method and conjugate for selectively targeting activated hematopoietic cells, e.g., macrophage or T-lymphocyte cells, are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against HIV, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into activated, HIV-infected cells, e.g., activated, HIV-infected macrophage and T-lymphocyte cells. An exemplary embodiment of the invention provides an antisense compound directed to the HIV Vif gene, causing the production of defective HIV virions in an infected individual.
A method of achieving selective uptake of a substantially uncharged antisense compound into activated human macrophage or T lymphocyte cells, comprising
Dependencies are inferred from the claim text.